Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 1/20 | 0.51 |
| ▸ | CDC25C | P30307 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | ATP4A | P20648 | 15/20 | 0.47 |
| ▸ | ATP4B | P51164 | 15/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265820 | 0.90 | CDC25A (0.53) | CDC25ACDC25BCDC25CDUSP3ATP4A | |
| SCHEMBL4267045 | 0.76 | CDC25A (0.49) | CDC25ACDC25BCDC25CDUSP3ATP4A | |
| SCHEMBL4269954 | 0.76 | CDC25A (0.59) | CDC25ACDC25BCDC25CDUSP3ATP4A | |
| SCHEMBL4274765 | 0.76 | CDC25A (0.42) | CDC25ACDC25BCDC25CDUSP3ATP4A | |
| SCHEMBL4279335 | 0.72 | MAPT (0.74) | CDC25ACDC25BCDC25CDUSP3 | |
| SCHEMBL14531237 | 0.72 | CDC25A (0.69) | CDC25ACDC25BCDC25CDUSP3 | |
| SCHEMBL3699421 | 0.70 | ATP4A (0.61) | ATP4AATP4B | |
| SCHEMBL3597116 | 0.70 | SREBF2 (0.57) | — | |
| SCHEMBL13545609 | 0.70 | SREBF2 (0.57) | — | |
| SCHEMBL10663111 | 0.69 | ATP4A (0.70) | ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605172-B2 | Thiazolo-naphthyl acids | WYETH (US) | 2009-10-20 | — | — | US | claimed |
| US-20060052420-A1 | Plasminogen activator inhibitor-1 (PAI-1) modulators; 3-phenyl-2-{[6-(2-phenyl-1,3-thiazol-4-yl)-2-naphthyl]oxy}propanoic acid; thrombosis; cardiovascular disease | WYETH (US) | 2006-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052420-A1 | Plasminogen activator inhibitor-1 (PAI-1) modulators; 3-phenyl-2-{[6-(2-phenyl-1,3-thiazol-4-yl)-2-naphthyl]oxy}propanoic acid; thrombosis; cardiovascular disease | SERPINE1, PLAT, SERPINC1 | CDC25A 2671/4885CDC25B 3732/4885CDC25C 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.